Yuhan Corporation

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
71,500 ^KRW	-1.11%		+2.00%	+3.92%

Apr. 24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
Mar. 07	Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ImmuneOncia Therapeutics Inc. announced that it has received KRW 24.5 billion in funding from Yuhan Corporation, Premier Partners, LLC, K2 Investment Partners LLC, BNH Investment LLC, E&Investment, Inc., Hanyang Securities Co., Ltd., Investment Arm and other investors

January 16, 2022

ImmuneOncia Therapeutics Inc. announced that it has received KRW 24,500,000,000 in a round of funding on January 17, 2022. The transaction included participation from returning investor Yuhan Corporation, new investors including Premier Partners, LLC, K2 Investment Partners LLC, BNH Investment LLC, E&Investment, Inc. and Hanyang Securities Co., Ltd., Investment Arm.

Latest news about Yuhan Corporation

Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	Apr. 24	MT
Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Progen Co., Ltd. announced that it has received KRW 9.71405799 billion in funding from Yuhan Corporation and other investors	Feb. 07	CI
COSON Co., Ltd. announced that it expects to receive KRW 3 billion in funding from Cruise Holdings Co., Ltd., Yuhan Corporation and other investors.	Dec. 28	CI
Yuhan Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	Nov. 02	CI
Contagion fears spread as China property sector cash crunch intensifies	23-08-14	RE
Yuhan Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Country Garden shares dive after bond trading halted, fans further economic distress	23-08-13	RE
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.	23-07-27	CI
Yuhan Corporation and J INTS BIO Inks a Licensing Agreement for A New Drug Candidate Targeting HER2 NSCLC	23-05-31	CI
Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
China Domestic Tourism Sector Seen to Recover in Summer 2023	23-02-22	MT
Yuhan Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Sector Update: Tech Stocks Recovering Ahead of Friday Close	22-09-16	MT

Chart Yuhan Corporation

Duration

Period

More charts

Company Profile

Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yuhan Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

71,500 KRW

Average target price

85,674 KRW

Spread / Average Target

+19.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
YUHAN CORPORATION	+3.92%	3.92B
MERCK KGAA	+4.16%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-17.03%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+37.51%	4.22B
INDIVIOR PLC	+18.14%	2.55B
BETTA PHARMACEUTICALS CO., LTD.	-24.13%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.70%	2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.92B
SUPERNUS PHARMACEUTICALS, INC.	+1.28%	1.66B

Specialty & Advanced Pharmaceuticals

Yuhan Corporation

Equities

A000100

KR7000100008

Pharmaceuticals

ImmuneOncia Therapeutics Inc. announced that it has received KRW 24.5 billion in funding from Yuhan Corporation, Premier Partners, LLC, K2 Investment Partners LLC, BNH Investment LLC, E&Investment, Inc., Hanyang Securities Co., Ltd., Investment Arm and other investors

Latest news about Yuhan Corporation

Chart Yuhan Corporation

Company Profile

Income Statement Evolution

Ratings for Yuhan Corporation

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals